Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2004 1
2006 2
2007 1
2008 1
2009 1
2010 1
2012 2
2013 2
2014 3
2015 6
2016 15
2017 8
2018 6
2019 8
2020 12
2021 19
2022 12
2023 18

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Diet-Derived Circulating Antioxidants and Risk of Coronary Heart Disease: A Mendelian Randomization Study.
Luo J, le Cessie S, van Heemst D, Noordam R. Luo J, et al. J Am Coll Cardiol. 2021 Jan 5;77(1):45-54. doi: 10.1016/j.jacc.2020.10.048. J Am Coll Cardiol. 2021. PMID: 33413940 Free article.
BACKGROUND: Previously, observational studies have identified associations between higher levels of dietary-derived antioxidants and lower risk of coronary heart disease (CHD), whereas randomized clinical trials showed no reduction in CHD ris …
BACKGROUND: Previously, observational studies have identified associations between higher levels of dietary-derived antioxidants and …
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
McMurray JJV, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Hou FF, Rossing P, Sjöström CD, Solomon SD, Toto RD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. McMurray JJV, et al. JACC Heart Fail. 2021 Nov;9(11):807-820. doi: 10.1016/j.jchf.2021.06.017. Epub 2021 Aug 23. JACC Heart Fail. 2021. PMID: 34446370 Free article. Clinical Trial.
OBJECTIVES: The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). ...(A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardio …
OBJECTIVES: The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients …
Lung function and cardiovascular disease: a two-sample Mendelian randomisation study.
Higbee DH, Granell R, Sanderson E, Davey Smith G, Dodd JW. Higbee DH, et al. Eur Respir J. 2021 Sep 9;58(3):2003196. doi: 10.1183/13993003.03196-2020. Print 2021 Sep. Eur Respir J. 2021. PMID: 33574079 Free article.
BACKGROUND: Observational studies suggest an association between reduced lung function and risk of coronary artery disease and ischaemic stroke, independent of shared cardiovascular risk factors such as cigarette smoking. ...Reduced force …
BACKGROUND: Observational studies suggest an association between reduced lung function and risk of coronary artery d …
Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement.
Li JJ, Ma CS, Zhao D, Yan XW; Beijing Heart Society and Expert Committee. Li JJ, et al. JACC Asia. 2022 Nov 15;2(6):653-665. doi: 10.1016/j.jacasi.2022.08.015. eCollection 2022 Nov. JACC Asia. 2022. PMID: 36444328 Free PMC article. Review.
Elevated concentration of lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral artery disease, and so on. Emerging data suggest that Lp(a) contribu …
Elevated concentration of lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, inc …
Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study.
Zheng J, Xu M, Yang Q, Hu C, Walker V, Lu J, Wang J, Liu R, Xu Y, Wang T, Zhao Z, Yuan J, Burgess S, Au Yeung SL, Luo S, Anderson EL, Holmes MV, Smith GD, Ning G, Wang W, Gaunt TR, Bi Y. Zheng J, et al. EBioMedicine. 2023 Oct;96:104803. doi: 10.1016/j.ebiom.2023.104803. Epub 2023 Sep 19. EBioMedicine. 2023. PMID: 37734206 Free PMC article.
METHODS: Genetic variants close to metformin-targeted genes associated with expression of the corresponding genes and glycated haemoglobin (HbA(1c)) level were used to proxy therapeutic effects of seven metformin-related drug targets. ...One-sample MR …
METHODS: Genetic variants close to metformin-targeted genes associated with expression of the corresponding genes and g …
Sclerostin and Cardiovascular Disease.
Tobias JH. Tobias JH. Curr Osteoporos Rep. 2023 Oct;21(5):519-526. doi: 10.1007/s11914-023-00810-w. Epub 2023 Jul 25. Curr Osteoporos Rep. 2023. PMID: 37490188 Free PMC article. Review.
RECENT FINDINGS: Randomised controlled trials of treatment with the anti-sclerostin antibody, romosozumab, have yielded conflicting evidence with respect to possible adverse effects of sclerostin inhibition on CVD risk. To further examine the causal relationship bet …
RECENT FINDINGS: Randomised controlled trials of treatment with the anti-sclerostin antibody, romosozumab, have yielded conflicting evidence …
Effect of Disclosing Genetic Risk for Coronary Heart Disease on Information Seeking and Sharing: The MI-GENES Study (Myocardial Infarction Genes).
Brown SN, Jouni H, Marroush TS, Kullo IJ. Brown SN, et al. Circ Cardiovasc Genet. 2017 Aug;10(4):e001613. doi: 10.1161/CIRCGENETICS.116.001613. Circ Cardiovasc Genet. 2017. PMID: 28779015 Free PMC article.
BACKGROUND: Whether disclosing genetic risk for coronary heart disease (CHD) to individuals influences information seeking and information sharing is not known. We hypothesized that disclosing genetic …
BACKGROUND: Whether disclosing genetic risk for coronary heart disease (CHD) to individuals influe …
The role of miRNAs in cardiovascular disease risk factors.
Jones Buie JN, Goodwin AJ, Cook JA, Halushka PV, Fan H. Jones Buie JN, et al. Atherosclerosis. 2016 Nov;254:271-281. doi: 10.1016/j.atherosclerosis.2016.09.067. Epub 2016 Sep 22. Atherosclerosis. 2016. PMID: 27693002 Free PMC article. Review.
Coronary artery disease and atherosclerosis are complex pathologies that develop over time due to genetic and environmental factors. Differential expression of miRNAs has been identified in patients with coronary artery disease and atheroscleros …
Coronary artery disease and atherosclerosis are complex pathologies that develop over time due to genetic and environme …
CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.
Ellithi M, Baye J, Wilke RA. Ellithi M, et al. Pharmacogenomics. 2020 Aug;21(12):889-897. doi: 10.2217/pgs-2020-0046. Epub 2020 Jul 29. Pharmacogenomics. 2020. PMID: 32723143 Free PMC article. Review.
Many initial successes in precision medicine occurred in the context of genes encoding the cytochromes P450 (CYP enzymes). CYP2C19 activates the antiplatelet drug clopidogrel, and polymorphisms in the CYP2C19 gene are known to alter the outcome for patients taking c …
Many initial successes in precision medicine occurred in the context of genes encoding the cytochromes P450 (CYP enzymes). CYP2C19 ac …
Relationship of SELE A561C and G98T Variants With the Susceptibility to CAD.
Liao B, Chen K, Xiong W, Chen R, Mai A, Xu Z, Dong S. Liao B, et al. Medicine (Baltimore). 2016 Feb;95(8):e1255. doi: 10.1097/MD.0000000000001255. Medicine (Baltimore). 2016. PMID: 26937892 Free PMC article. Review.
Published genetic association studies have produced controversial results regarding the association of SELE gene polymorphisms (A516C and G98T) and CAD susceptibility. ...The summary OR was greatest in individuals carrying the CC genotype (OR = 1.91, 95% CI, …
Published genetic association studies have produced controversial results regarding the association of SELE gene polymo …
111 results